Skip to main content

Avexitide: PBH Evidence, LUCIDITY Results and Access Status

By the Peptide Dossier Editorial TeamUpdated How we source

Published

Avexitide is an investigational GLP-1 receptor antagonist being developed for post-bariatric hypoglycemia, particularly after Roux-en-Y gastric bypass. Unlike GLP-1 receptor agonists used for diabetes or weight management, it blocks the receptor to reduce an exaggerated insulin response. Published early trials support that approach. Amylyx reported positive Phase 3 LUCIDITY topline results in August 2026, but those sponsor findings and a planned regulatory application are not an approval. 1–5

Avexitide at a glance

QuestionCurrent evidence context
Other nameExendin (9–39), a GLP-1 receptor antagonist
Main development settingPost-bariatric hypoglycemia, or PBH, after Roux-en-Y gastric bypass
Published controlled evidencePREVENT, an 18-participant Phase 2 crossover study
Additional published evidenceA 16-participant Phase 2b study covering several upper gastrointestinal surgical histories
Phase 3 updateSponsor-reported 55% reduction versus placebo in the composite rate of Level 2 and Level 3 hypoglycemic events through week 16
Current access contextInvestigational; an eligibility-limited US expanded access program is described by the sponsor
What it is notAn established weight-loss treatment, an acute rescue medicine or an approved self-treatment protocol

Sources: primary publications and registry checked November 14, 2026; expanded sponsor findings checked November 16, 2026. 1–5,7

Why blocking GLP-1 can make sense in this condition

GLP-1 is commonly discussed through medicines that activate its receptor. The clinical question behind avexitide is different: can blocking GLP-1 signaling reduce inappropriate post-meal insulin secretion in people with PBH? The direction of the intervention matters. Sharing a receptor name does not make two drugs interchangeable or mean they are being developed for the same problem. 1,4

PBH usually involves low blood glucose after meals in someone who has undergone bariatric surgery. The Society for Endocrinology guideline describes a typical pattern around two to four hours after eating and emphasizes confirming the relationship between symptoms, low glucose and symptom resolution. A history of surgery plus tiredness or a device alarm alone does not establish the diagnosis. Alternative causes need consideration. 6

The rationale for avexitide therefore starts with a defined condition rather than a general desire to change appetite or body weight. Its development asks whether a targeted receptor intervention can reduce clinically important hypoglycemia. That is a different outcome from the weight-loss endpoints discussed in our GLP-1 medication guide.

For readers, the practical distinction is simple: classify the drug by what it does at the receptor, then identify the population and outcome actually studied. The phrase “GLP-1 peptide” is too broad to answer either question. Avexitide evidence should not be borrowed to support an unrelated peptide, a product sold under a research label or an untested combination.

The evidence map: three studies, three different questions

StudyPopulation and designMain contributionImportant limitation
PREVENT, published 202118 women with PBH; placebo period followed by two active regimens in randomized sequenceControlled meal-test and outpatient hypoglycemia findingsSmall, short study; placebo came first rather than having a fully randomized sequence of all three periods
Phase 2b, published 202616 participants; baseline run-in followed by two active regimens in randomized orderFindings across several surgical histories and patient-reported measuresActive treatment compared with baseline, not a concurrent placebo arm
LUCIDITY, NCT06747468Parallel-group, double-blind, placebo-controlled Phase 3 trialLarger, longer test of event-rate reductionResults discussed here are sponsor-reported topline findings, not a substituted full peer-reviewed analysis

The design column is as important as the result column. The same percentage can mean something different when it describes a laboratory meal challenge, a comparison with a pretreatment baseline or a randomized comparison with placebo. 1–4

In the PREVENT report, Level 2 hypoglycemia meant a self-monitored glucose below 54 mg/dL; Level 3 meant a severe event with altered mental or physical function requiring assistance. The severity category is therefore not simply another numeric glucose cutoff. 1

A useful evidence review should let a reader trace each claim back to its study rather than blend all findings into one success rate. Here, “controlled,” “randomized” and “crossover” describe particular features. They should not be treated as generic labels that erase the order of treatment, the availability of a comparator or the amount of follow-up.

What PREVENT found

In PREVENT, all 18 participants received a 14-day placebo period, followed by avexitide 30 mg twice daily and 60 mg once daily, each for 14 days in randomized order. During mixed-meal testing, the two regimens increased the lowest glucose concentration by 21% and 26% compared with placebo and reduced peak insulin by 23% and 21%, respectively. The paper also reports fewer hypoglycemic events outside the meal test. 1

Those findings connect the proposed mechanism with measured human outcomes. The study was short and enrolled women with a selected PBH presentation, however, so it cannot settle long-term safety or establish identical effects in every surgical population. The placebo-first design also deserves attention when interpreting period effects. 1

The trial doses identify what researchers evaluated. They are not consumer instructions. For a research reader, their value is to define the intervention precisely enough to compare publications and understand how the program developed. Leaving the regimen unspecified makes a study difficult to interpret; turning it into a personal dosing schedule goes beyond what an evidence summary can justify.

What the newer Phase 2b study adds

The Phase 2b publication included 16 participants with clinically important hypoglycemia after Roux-en-Y gastric bypass, sleeve gastrectomy, total gastrectomy or Nissen fundoplication. After a 14-day run-in, participants received two active regimens in randomized order. Compared with baseline, daytime Level 2 events measured by continuous glucose monitoring fell by 47.7% and 59.0%. 2

The broader surgical histories are useful because they explore whether the same biological strategy may matter beyond the original bypass population. But a small study spanning several procedures does not supply a reliable estimate for each subgroup. The publication reports consistent improvements across surgical subtypes; that should not be inflated into a claim of equally established efficacy for every operation. 2

The baseline comparison is another boundary. A run-in period tells investigators what happened before active treatment in those participants. It does not provide the same protection against time-related influences as a concurrent placebo comparison. The most defensible interpretation is that this study adds supportive evidence and informs further testing, while leaving a stronger comparative question for a randomized controlled trial.

LUCIDITY: the Phase 3 result and what remains to be seen

Amylyx’s August 18, 2026 announcement reports that LUCIDITY enrolled 78 adults with PBH after Roux-en-Y gastric bypass. The company reported a 55% reduction versus placebo in the composite rate of Level 2 and Level 3 hypoglycemic events through week 16, with p=0.000003. It also reported that the secondary efficacy endpoints were met. These are attributed sponsor findings. 4

The current registry describes a randomized, double-blind, parallel-group study. Its primary efficacy measure combines Level 2 events measured by self-monitoring with independently adjudicated Level 3 events. The registry also lists safety and anti-drug-antibody outcomes. As checked on November 14, the record had no posted results section and listed the study as active, not recruiting. 3

There is a small but meaningful provenance difference: the registry retains an estimated enrollment of 75, whereas the sponsor’s results announcement reports 78 enrolled participants. This page preserves both descriptions instead of presenting the estimate as an observed final count. The registry’s last posted update was August 24, 2026. 3,4

A topline release can report a major result before readers have the full analysis. The November 14 sponsor release subsequently reported least-squares mean composite rates of 0.55 versus 1.24 events per week and a more precise p-value of 0.0000034. Component reductions versus placebo were 63% for self-monitored Level 2 events, 47% for adjudicated Level 3 events and 42% for CGM-detected Level 2 events. Completion was 45 of 47 participants receiving avexitide and 28 of 31 receiving placebo. These remain sponsor-reported analyses, not a full peer-reviewed report. Uncertainty intervals, missing-data methods and detailed safety tables still matter. 10 A very small p-value does not supply those missing details or describe the size of benefit for a particular person.

Understanding a 55% reduction in event rate

A reduction in event rate is not the same as the percentage of participants who were cured, the percentage who became symptom-free or a percentage-point change in glucose. It compares how frequently defined events occurred over an observation period. A combined endpoint also needs its components examined separately: a reduction in the total does not automatically describe the effect on every component.

Here is a purely illustrative example, not a reconstruction of LUCIDITY: reducing an event rate from 10 to 4.5 events over comparable observation time would be a 55% relative reduction. Reducing it from two to 0.9 would also be a 55% relative reduction. The absolute number of events avoided would differ. This is why the underlying rates and time period matter alongside the relative figure.

An event-rate claim should also specify how events were captured. A glucose monitor, a finger-stick reading and an independently reviewed severe episode produce related but different evidence. The LUCIDITY registry distinguishes these measurements. Keeping that distinction makes the eventual full report easier to assess and prevents a combined headline from being mistaken for one universal clinical outcome. 3

Safety: encouraging observations are not a complete risk profile

The published Phase 2b study reported no serious adverse events and no discontinuations due to adverse events in its 16 participants. That is useful information about the people and treatment periods observed; its size and duration limit what can be inferred about uncommon or delayed problems. 2

For LUCIDITY, Amylyx reported that most adverse events were mild or moderate, with diarrhea, injection-site redness and bruising the most common. The company reported no serious adverse events related to avexitide treatment. “No treatment-related serious adverse events” does not mean “no adverse events,” and causality judgments should remain distinct from simply counting events. 4

The next useful safety questions are how frequent events were in each group, whether they affected treatment continuation, and what longer observation adds. An open-label extension can contribute longer-term observations, but it has a different comparator structure from the double-blind period. Readers should know which period a safety statement refers to.

The peptide safety guide provides a broader framework for separating evidence about a molecule from claims about an individual product. Trial findings do not establish the identity, composition or suitability of a seller’s vial.

Approval, availability and the November 2026 update

In its November 5 update, Amylyx continued to describe avexitide as investigational, said a US New Drug Application submission was planned by the end of 2026 and announced a LUCIDITY presentation for November 15. The November 14 release also announced the November 15 presentation. That scheduled date has now passed; this page has reviewed the dated release rather than claiming to have watched or independently verified delivery of the presentation. 10 5

An application plan is not an application receipt, a regulatory review decision or an approved indication. Similarly, a development designation is a different milestone from authorization to market a medicine. An evidence timeline should record the actual event and its source, rather than allowing optimistic language about a possible launch to stand in for a decision.

For someone researching access, the relevant questions are therefore separate: is there an approved product; is there an available clinical trial; and is there a qualifying access program? An answer to one does not establish the others. No approved retail price, insurance coverage promise or launch date is established by the sources summarized here.

Expanded access: a clinician-led pathway, not general availability

Amylyx’s current policy describes a US expanded access program for adults with PBH after Roux-en-Y gastric bypass who have a serious unmet need, cannot participate in an ongoing trial and have exhausted available treatment options. It directs interested people to their treating clinician and says eligibility and participation are not guaranteed. 7

FDA describes expanded access as a potential treatment pathway outside clinical trials for serious or immediately life-threatening conditions when comparable or satisfactory alternatives are unavailable. The potential benefit must justify the potential risk, and access must not interfere with development trials. FDA also emphasizes that the investigational product has not been approved for the use and may cause unexpected serious side effects. 8

That framework explains why an access announcement should not be translated into “anyone can get a prescription.” A program is a defined pathway with conditions, review and oversight. It is also not interchangeable with buying material labeled for research. The appropriate next step for an individual is to discuss their clinical history and the current program with their care team, rather than infer eligibility from an article.

Useful questions for a clinical or research discussion

For a person already being evaluated for possible PBH, a productive discussion starts with the condition rather than the investigational drug. Ask how the diagnosis was established, which alternative causes were considered, and how symptoms and glucose observations should be documented. Treatment decisions depend on that clinical context, not simply on matching a symptom to a search result. 6

If a trial or access pathway is being considered, useful questions include:

  • Which surgical histories and disease characteristics does the current protocol cover?
  • What is known from a published trial, and what is currently known only from a sponsor update?
  • How are hypoglycemic events measured, and which outcomes matter most for daily safety?
  • What monitoring, follow-up and treatment-continuation requirements apply?
  • What happens if the treatment is stopped or a participant leaves the program?

Our study explorer offers a separate way to examine selected trial records. It is a navigation tool, not proof that every trial or compound is included.

Severe low glucose can involve confusion, loss of consciousness or seizures. NIDDK advises emergency help for severe episodes; do not wait for an investigational treatment or an online explanation when urgent care is needed. This general hypoglycemia safety resource is written principally for people with diabetes, rather than being a PBH-specific treatment protocol. 9

Frequently asked questions

Is avexitide a weight-loss peptide?

That is not the indication addressed by the PBH evidence summarized here. The research target is inappropriate insulin secretion and hypoglycemic events after specified surgeries. It should not be grouped with GLP-1 receptor agonists simply because the receptor name overlaps. 1,3

Is avexitide the same as exendin (9–39)?

The PREVENT paper identifies avexitide as exendin (9–39). This naming connection helps readers find earlier research. It does not establish that every product bearing either name is equivalent to the controlled study material. 1

Does the Phase 3 announcement prove approval?

No. The November 5 sponsor update still describes an investigational medicine and a planned application. This page distinguishes that dated status from an actual regulatory decision. 5

Can the different trial percentages be ranked directly?

No. PREVENT includes meal-test outcomes and a placebo period; Phase 2b compares active treatment with baseline; LUCIDITY reports a placebo-controlled event-rate endpoint over a different duration. A higher percentage from one row does not by itself identify the better regimen or a more reliable result.

What should the next update add?

The next substantive update should check whether the planned presentation occurred, whether a full report or registry results became available, and whether a regulatory milestone actually changed. Any new source should retain its publication date, population, comparator and analysis context.

References

  1. Craig CM et al. PREVENT: randomized placebo-controlled crossover trial. Journal of Clinical Endocrinology & Metabolism, 2021. PMID 33616643; DOI 10.1210/clinem/dgab103. Primary publication and abstract; industry-sponsored study.

  2. Craig C et al. Phase 2b study following bariatric and other upper gastrointestinal surgeries. Metabolism, 2026. PMID 42744082; DOI 10.1016/j.metabol.2026.156773. Primary abstract checked; first publication September 15, 2026.

  3. ClinicalTrials.gov: LUCIDITY, NCT06747468. Public API checked November 14; last posted update August 24, 2026; estimated enrollment remains distinct from sponsor-reported actual enrollment.

  4. Amylyx: LUCIDITY topline results, August 18, 2026. Sponsor report; not substituted for a full peer-reviewed Phase 3 analysis.

  5. Amylyx: third-quarter update, November 5, 2026. Dated development and planned-presentation update.

  6. Society for Endocrinology guideline, 2024. DOI 10.1530/EC-23-0285; PMID 38451861. Specialist guideline for PBH diagnosis and management; historical guidance, not a 2026 approval decision.

  7. Amylyx global access policy and avexitide program. Sponsor eligibility and access information checked November 14, 2026; availability can change.

  8. FDA: Expanded Access. Official explanation of investigational treatment access and its limitations.

  9. NIDDK: Low Blood Glucose (Hypoglycemia). General hypoglycemia symptoms and emergency context, not a PBH-specific prescribing guide.

  10. Amylyx: expanded LUCIDITY results, November 14, 2026. Sponsor release checked November 16; not a peer-reviewed report.

Editorial method: The Peptide Dossier Editorial Team used AI-assisted drafting and checked primary abstracts, the public trial registry, the published PREVENT report, dated sponsor updates and authoritative patient/regulatory sources. This is a selected evidence synthesis, not a systematic review or clinician review. Source checks: original studies and registry November 14, 2026; expanded sponsor report November 16, 2026. See our editorial policy and publisher information.